Physician profile
Fei Gu
NPI 1033302625
$14,912.76
in general payments reported to CMS, 2019-2025
57 companies · $1,600 in 2025
The $1,600 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $438 · 2020: $4,241 · 2021: $974 · 2022: $723 · 2023: $4,172 · 2024: $2,765 · 2025: $1,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,487 · Consulting Fee: $1,950 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,486.66 |
| Consulting Fee | $1,950.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $3,603.43 | 2020-2023 | |
| Beigene USA, INC. | $2,115.18 | 2020-2025 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $957.34 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $909.48 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Astrazeneca Pharmaceuticals Lp | $638.87 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Celgene Corporation | $438.43 | 2019-2025 | Reblozyl, Opdualag |
| Incyte Corporation | $436.67 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Merck Sharp & Dohme LLC | $431.89 | 2020-2025 | Keytruda, Welireg |
| Janssen Biotech, INC. | $429.46 | 2021-2025 | Erleada, Darzalex, Talvey |
| Seagen INC. | $407.44 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Genentech USA, INC. | $357.60 | 2019-2025 | Polivy, Lunsumio, Alecensa |
| Pfizer INC. | $332.47 | 2019-2025 | |
| Gilead Sciences, INC. | $325.89 | 2021-2024 | Trodelvy |
| Exelixis INC. | $294.34 | 2020-2025 | Cabometyx |
| Daiichi Sankyo INC. | $271.03 | 2023-2025 | Enhertu, Injectafer |
Show all 57 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $226.15 | 2022-2025 | |
| Amgen INC. | $213.53 | 2020-2023 | Lumakras, Vectibix, Xgeva |
| Alexion Pharmaceuticals, INC. | $194.96 | 2023-2024 | Ultomiris |
| Genzyme Corporation | $178.45 | 2019-2025 | |
| Rigel Pharmaceuticals, INC. | $177.63 | 2021-2024 | Tavalisse, Rezlidhia |
| Stemline Therapeutics INC. | $151.38 | 2023-2025 | Orserdu |
| Astellas Pharma US INC | $129.04 | 2019-2025 | Xtandi |
| Verastem, INC. | $126.87 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $118.46 | 2021-2025 | |
| Sobi, INC | $118.11 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $108.65 | 2023-2025 | Iclusig, Alunbrig |
| Lilly USA, LLC | $108.32 | 2019-2024 | Retevmo, Jaypirca, Verzenio |
| Karyopharm Therapeutics INC. | $87.09 | 2020-2025 | Xpovio |
| Genmab U.S., INC. | $75.93 | 2023-2024 | Epkinly |
| Aveo Pharmaceuticals, INC. | $72.24 | 2024 | |
| Puma Biotechnology, INC. | $67.97 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $66.95 | 2023-2025 | Libtayo |
| Kite Pharma, INC. | $64.78 | 2023-2025 | Yescarta |
| Blueprint Medicines Corporation | $62.69 | 2023 | Ayvakit |
| Mirati Therapeutics, INC. | $53.20 | 2024 | Krazati |
| Jazz Pharmaceuticals INC. | $50.31 | 2021-2023 | |
| Array Biopharma INC | $48.29 | 2019-2025 | Mektovi, Braftovi, Lorbrena |
| Ipsen Biopharmaceuticals, INC | $45.83 | 2024 | Onivyde |
| Heron Therapeutics, INC. | $36.67 | 2022-2023 | Cinvanti |
| Emd Serono, INC. | $35.34 | 2021-2025 | |
| Legend Biotech USA INC. | $35.02 | 2025 | Carvykti |
| Glaxosmithkline, LLC. | $31.20 | 2024-2025 | Ojjaara |
| Geron Corporation | $29.36 | 2025 | Rytelo |
| Tempus Ai, INC | $27.43 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $26.40 | 2023 | Imbruvica |
| Springworks Therapeutics, INC. | $23.45 | 2024 | Ogsiveo |
| Adaptive Biotechnologies Corporation | $20.74 | 2023 | Clonoseq |
| Cti Biopharma Corp. | $19.17 | 2023 | Vonjo |
| Servier Pharmaceuticals LLC | $18.65 | 2024 | |
| Taiho Oncology, INC. | $17.03 | 2024 | |
| Deciphera Pharmaceuticals INC. | $16.07 | 2025 | Qinlock, Romvimza |
| Apellis Pharmaceuticals, INC. | $15.08 | 2022 | |
| G1 Therapeutics, INC. | $14.18 | 2022 | |
| Fresenius Kabi USA, LLC | $13.70 | 2024 | Stimufend |
| Pharmaessentia USA Corporation | $12.95 | 2023 | Besremi |
| Eusa Pharma (US) LLC | $12.62 | 2021 | |
| Sun Pharmaceutical Industries INC. | $11.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fei Gu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.